Journot V - Search Results

1

Self-reported symptoms after initiation of a protease inhibitor in HIV-infected patients and their impact on adherence to HAART.

Duran S, Spire B, Raffi F, Walter V, Bouhour D, Journot V, Cailleton V, Leport C, Moatti JP; APROCO Cohort Study Group. Duran S, et al. Among authors: journot v. HIV Clin Trials. 2001 Jan-Feb;2(1):38-45. doi: 10.1310/R8M7-EQ0M-CNPW-39FC. HIV Clin Trials. 2001. PMID: 11590513 Clinical Trial.

2

The dynamic of adherence to highly active antiretroviral therapy: results from the French National APROCO cohort.

Carrieri P, Cailleton V, Le Moing V, Spire B, Dellamonica P, Bouvet E, Raffi F, Journot V, Moatti JP; APROCO study group. Carrieri P, et al. Among authors: journot v. J Acquir Immune Defic Syndr. 2001 Nov 1;28(3):232-9. doi: 10.1097/00042560-200111010-00005. J Acquir Immune Defic Syndr. 2001. PMID: 11694829

3

Incidence of and risk factors for adverse drug reactions in a prospective cohort of HIV-infected adults initiating protease inhibitor-containing therapy.

Duval X, Journot V, Leport C, Chêne G, Dupon M, Cuzin L, May T, Morlat P, Waldner A, Salamon R, Raffi F; Antiprotease Cohort (APROCO) Study Group. Duval X, et al. Among authors: journot v. Clin Infect Dis. 2004 Jul 15;39(2):248-55. doi: 10.1086/422141. Epub 2004 Jul 1. Clin Infect Dis. 2004. PMID: 15307035

4

Viremia copy-years as a predictive marker of all-cause mortality in HIV-1-infected patients initiating a protease inhibitor-containing antiretroviral treatment.

Chirouze C, Journot V, Le Moing V, Raffi F, Piroth L, Reigadas S, Cassuto JP, Chêne G, Leport C, Hoen B; ANRS CO 08 Aproco-Copilote Study Group. Chirouze C, et al. Among authors: journot v. J Acquir Immune Defic Syndr. 2015 Feb 1;68(2):204-8. doi: 10.1097/QAI.0000000000000416. J Acquir Immune Defic Syndr. 2015. PMID: 25590273

5

Incidence and risk factors of bacterial pneumonia requiring hospitalization in HIV-infected patients started on a protease inhibitor-containing regimen.

Le Moing V, Rabaud C, Journot V, Duval X, Cuzin L, Cassuto JP, Al Kaied F, Dellamonica P, Chêne G, Raffi F; APROCO Study Group. Le Moing V, et al. Among authors: journot v. HIV Med. 2006 May;7(4):261-7. doi: 10.1111/j.1468-1293.2006.00370.x. HIV Med. 2006. PMID: 16630039 Free article.

6

Pregnancy may be followed by an inflexion of the immune reconstitution in HIV-infected women who receive antiretroviral drugs before conception.

Le Moing V, Taïeb A, Longuet P, Lewden C, Delcey V, Drobacheff MC, Chêne G, Leport C; ANRS CO8 (APROCO-COPILOTE) study group. Le Moing V, et al. HIV Med. 2008 Nov;9(10):897-900. doi: 10.1111/j.1468-1293.2008.00641.x. Epub 2008 Sep 14. HIV Med. 2008. PMID: 18795961 Free PMC article.

7

Plasma levels of indinavir and nelfinavir at time of virologic response may have a different impact on the risk of further virologic failure in HIV-infected patients.

Le Moing V, Peytavin G, Journot V, Cottalorda J, Bouvet E, Chêne G, Préau M, de Boever CM, Leport C, Raffi F; Antiprotease Cohort (APROCO) Study Group. Le Moing V, et al. Among authors: journot v. J Acquir Immune Defic Syndr. 2003 Dec 15;34(5):497-9. doi: 10.1097/00126334-200312150-00008. J Acquir Immune Defic Syndr. 2003. PMID: 14657760

8

Role of long-term nucleoside-analogue therapy in lipodystrophy and metabolic disorders in human immunodeficiency virus-infected patients.

Chêne G, Angelini E, Cotte L, Lang JM, Morlat P, Rancinan C, May T, Journot V, Raffi F, Jarrousse B, Grappin M, Lepeu G, Molina JM. Chêne G, et al. Among authors: journot v. Clin Infect Dis. 2002 Mar 1;34(5):649-57. doi: 10.1086/338811. Epub 2002 Jan 24. Clin Infect Dis. 2002. PMID: 11810598 Clinical Trial.

9

Once-daily combination therapy with emtricitabine, didanosine, and efavirenz in human immunodeficiency virus-infected patients.

Molina JM, Ferchal F, Rancinan C, Raffi F, Rozenbaum W, Sereni D, Morlat P, Journot V, Decazes JM, Chêne G. Molina JM, et al. Among authors: journot v. J Infect Dis. 2000 Aug;182(2):599-602. doi: 10.1086/315711. Epub 2000 Jul 13. J Infect Dis. 2000. PMID: 10915095 Clinical Trial.

10

Analysis of undetectable HIV RNA using survival analysis: results must be interpreted carefully.

Thiébaut R, Jacqmin-Gadda H, Journot V, Ferchal F, Rancinan C, Molina JM, Chêne G; ALBI Study Group. Thiébaut R, et al. Among authors: journot v. HIV Clin Trials. 2003 Nov-Dec;4(6):417-20. doi: 10.1310/47L8-GTK1-R6Q2-4CUV. HIV Clin Trials. 2003. PMID: 14628285

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

43 results

Search Page